Beacon ADC

Maximize Your Data With the Most Complete Trial, Drug, and Commercial Database for ADCs

What We Cover

Beacon ADC is a manually curated database solution that includes clinical trial and drug records for preclinical, active, approved and discontinued:

  • ADC (Antibody Drug Conjugates)
  • Immunotoxins
  • SMDCs (Small Molecule Drug Conjugates)
  • Radioimmunoconjugates
  • Ligand Conjugated Nanoparticles
  • Liposomal Drug Conjugate and other comparable modalities

Commercial intelligence data expansion: Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more by downloading the factsheet.

How Beacon Helps

Here are a few example use cases that have benefitted our clients in accelerating their ADC development programs:

  • Benchmark drug development and clinical trial strategies against competitors.
  • Getting an in-depth competitive landscape overview of the competitors and their assets in the clinic.
  • Drastically reduce manual research time with our database solution which allows users to rapidly assemble data for analysis on targets, payloads and much more.
  • Identify new players and new assets in entering the clinic and monitor their progress.

How Beacon ADC Works

Search the trial and drug landscape by linker, payload and target alongside 20 other search criteria including disease, line of therapy, biomarker, sponsor etc. Instantly extract the data points you need to conduct more complex analyses.

Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the ADC space.

How We Target the Data

We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):

  • Clinical Trials Registries
  • Scientific Journals and Publications
  • Company Reports and Presentations
  • Press Releases
  • Conference Reports and Abstracts
  • Government and Regulatory Organizations
  • Newspapers and other media
  • Patents

Related Content

Exploring the Synergy of ADCs in Combination with Checkpoints – A Comprehensive Review

Find out more

The 2023 ADC Landscape Review

Find out more

The Rise of ADCs and Novel Drug Conjugates in Asia

Find out more

What Our Customers Say

“I look forward to using Beacon. It saves me hours of trawling through false positive results to my searches.”

Head of Competitive Intelligence
Multinational Pharmaceutical Company

Our ADC Expert


Jia He, PhD is the lead research analyst for ADC-related drugs and trials in the Beacon team.

Sign up to her weekly newsletter with the latest ADC landscape insights and updates with data from Beacon ADC.

Subscribe to Our ADC Newsletter

Other Beacon Solutions

Cancer Vaccine
Cell Therapy
Gene Therapy
Immune Tolerance
Oncolytic Viruses
Beacon Bispecific Logo


Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more

Find out more

Cancer Vaccine Logo 2021


Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.

Find out more

Beacon Checkpoint Logo


Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets

Find out more


Beacon Cell Therapy covers genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications

Find out more


Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.

Find out more

Beacon DDR Logo


Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.

Find out more

Beacon Gene Therapy Logo


From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.

Find out more


Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.

Find out more


Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.

Find out more

Beacon Oncolytic Viruses Logo


From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.

Find out more


Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.

Find out more

Beacon TPD Logo


Beacon TPD provides the solution you need to master the targeted protein degradation field.

Find out more

Any Questions? Contact Us

To learn how Beacon ADC can align, optimize, and maximize your trial, drug, and commercial intelligence, get in touch with our sales team.


Jake Morris & Eleni Taoula

ADC Account Managers

Contact the Team

About Beacon

Beacon is a world-leading data analysis subscription platform for drug, trial, and commercial intelligence. With unrivaled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information that gives you the confidence to progress your targeted drug therapies to patients.